Seagen 미래 성장

Future 기준 확인 5/6

Seagen은 연간 수입과 매출이 각각 71.8%와 22.6% 증가할 것으로 예상되고 EPS는 연간 71.5%만큼 증가할 것으로 예상됩니다.

주요 정보

71.8%

수익 성장률

71.5%

EPS 성장률

Biotechs 수익 성장	42.1%
매출 성장률	22.6%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	11 Dec 2023

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

DB:SGT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	4,080	130	421	564	13
12/31/2024	3,181	-354	32	96	16
12/31/2023	2,428	-758	-361	-372	17
9/30/2023	2,300	-750	-701	-540	N/A
6/30/2023	2,162	-725	-723	-590	N/A
3/31/2023	2,056	-649	-585	-487	N/A
12/31/2022	1,962	-610	-531	-454	N/A
9/30/2022	1,864	-637	-719	-658	N/A
6/30/2022	1,778	-740	-652	-590	N/A
3/31/2022	1,669	-690	-653	-590	N/A
12/31/2021	1,574	-674	-551	-499	N/A
9/30/2021	1,746	-333	-82	-26	N/A
6/30/2021	2,383	597	756	814	N/A
3/31/2021	2,273	661	736	800	N/A
12/31/2020	2,176	614	774	857	N/A
9/30/2020	1,864	472	571	656	N/A
6/30/2020	1,016	-256	-312	-228	N/A
3/31/2020	956	-314	-259	-176	N/A
12/31/2019	917	-159	-234	-164	N/A
9/30/2019	801	-304	-234	-176	N/A
6/30/2019	758	-280	-172	-127	N/A
3/31/2019	709	-124	-143	-114	N/A
12/31/2018	655	-223	-225	-204	N/A
9/30/2018	610	-162	-183	-182	N/A
6/30/2018	576	-45	-179	-179	N/A
3/31/2018	514	-177	-221	-203	N/A
12/31/2017	482	-126	-148	-119	N/A
9/30/2017	458	-121	-183	-132	N/A
6/30/2017	429	-203	N/A	-155	N/A
3/31/2017	416	-180	N/A	-143	N/A
12/31/2016	418	-140	N/A	-97	N/A
9/30/2016	406	-110	N/A	-101	N/A
6/30/2016	384	-105	N/A	-110	N/A
3/31/2016	366	-119	N/A	-124	N/A
12/31/2015	337	-120	N/A	-133	N/A
9/30/2015	318	-122	N/A	-135	N/A
6/30/2015	309	-111	N/A	-106	N/A
3/31/2015	301	-82	N/A	-64	N/A
12/31/2014	287	-76	N/A	-60	N/A
9/30/2014	280	-65	N/A	-33	N/A
6/30/2014	275	-73	N/A	9	N/A
3/31/2014	280	-63	N/A	6	N/A
12/31/2013	269	-63	N/A	-1	N/A
9/30/2013	266	-57	N/A	43	N/A
6/30/2013	245	-47	N/A	-12	N/A
3/31/2013	220	-58	N/A	9	N/A
12/31/2012	211	-54	N/A	11	N/A

애널리스트 미래 성장 예측

수입 대 저축률: SGT 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 0.5% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: SGT (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: SGT 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: SGT 의 수익(연간 22.6% ) German 시장( 5.7% 보다 빠르게 성장할 것으로 예상됩니다. 5.7% 연간).

고성장 수익: SGT 의 수익(연간 22.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: SGT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2023/12/14 15:47
장 마감 주가	2023/12/13 00:00
수익	2023/09/30
연간 수익	2022/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Seagen Inc. 33 애널리스트 중 17 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ishan Majumdar	Baptista Research
Emily Bodnar	Berenberg
George Farmer	BMO Capital Markets Equity Research

Seagen 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. Revises Earnings Guidance for the Year 2022

Seagen Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Third quarter 2023 earnings released: US$1.15 loss per share (vs US$1.03 loss in 3Q 2022)

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Second quarter 2023 earnings released: US$1.13 loss per share (vs US$0.73 loss in 2Q 2022)

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

First quarter 2023 earnings released: US$0.94 loss per share (vs US$0.74 loss in 1Q 2022)

Now 20% undervalued

Now 21% undervalued

Full year 2022 earnings released: US$3.31 loss per share (vs US$3.71 loss in FY 2021)

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Independent Director recently sold €937k worth of stock

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Third quarter 2022 earnings released: US$1.03 loss per share (vs US$1.61 loss in 3Q 2021)

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc

Second quarter 2022 earnings released: US$0.73 loss per share (vs US$0.47 loss in 2Q 2021)

Seagen Inc. Revises Earnings Guidance for the Year 2022

Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022

Merck Reportedly in Advanced Talks to Buy Seagen

Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab

Merck Reportedly Pushes Forward with Potential Deal for Seagen

Merck, Other Suitors Reportedly Interested in Acquiring Seagen

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA(R) (tucatinib) in Combination with Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

Seagen Announces Resignation of Clay Siegall as CEO

Seagen Inc., Annual General Meeting, May 13, 2022

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

First quarter 2022 earnings released: US$0.74 loss per share (vs US$0.67 loss in 1Q 2021)

Insufficient new directors

Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™ (Enfortumab Vedotin) for Locally Advanced or Metastatic Urothelial Cancer

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting

Seagen Inc. to Report Q1, 2022 Results on Apr 28, 2022

Astellas Pharma Inc. and Seagen Inc. Announce CHMP Confirms Positive Opinion for PADCEV™ (Enfortumab Vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

Seagen and Astellas Announce Initial Results of PADCEV (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Seagen Inc. Provides Earnings Guidance for the Year 2022

ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma

Seagen Inc. Announces Executive Changes

Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer

Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40

Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin)

Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib)

Seagen Inc. Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer

Japan’s MHLW Approves Astellas Pharma Inc. and Seagen Inc.'s PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer

U.S. Food and Drug Administration Grants Approval to TIVDAK

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측